Federal Register / Vol. 72, No. 244 / Thursday, December 20, 2007 / Notices 72367 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel, Design 

and Synthesis of Treatment Agents for Drug 

Abuse. 

Date: December 18, 2007. 

Time: 10:20 a.m. to 1 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6101 

Executive Boulevard, Rockville, MD 20852, 

(Telephone Conference Call). 

Contact Person: Lyle Furr, Contract Review 

Specialist, Office of Extramural Affairs, 

National Institute on Drug Abuse, NIH, 

DHHS, Room 220, MSC 8401, 6101 Executive 

Boulevard, Bethesda, MD 20892–8401, (301) 

435–1439, lf33c@nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.279, Drug Abuse and 

Addiction Research Programs, National 

Institutes of Health, HHS) 

Dated: December 11, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–6086 Filed 12–19–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel, 

MIDARP. 

Date: January 10, 2008. 

Time: 10 a.m. to 11 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6101 

Executive Boulevard, Rockville, MD 20852, 

(Telephone Conference Call). 

Contact Person: Nadine Rogers, PhD, 

Scientific Review Administrator, Office of 

Extramural Affairs, National Institute on 

Drug Abuse, NIH, DHHS, Room 220, MSC 

8401, 6101 Executive Boulevard, Bethesda, 

MD 20892–8401, 301–402–2105, 

rogersn2@nida.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.279, Drug Abuse and 

Addiction Research Programs, National 

Institutes of Health, HHS) 

Dated: December 11, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–6087 Filed 12–19–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office Of The Director, National 

Institutes Of Health; Notice of Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

Recombinant DNA Advisory Committee. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: Recombinant DNA 

Advisory Committee. 

Date: January 14, 2008. 

Time: 3 p.m. to 4 p.m. 

Agenda: Recombinant DNA Advisory 

Committee teleconference will meet to 

discuss the follow-up of a Serious Adverse 

Event on a Human Gene Transfer Trial (OBA 

Protocol #0504–705) Using an AdenoAssociated Viral Vector: Analysis of Its 

Scientific and Safety Implications. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Sixth Floor, 

C Wing, Room 6, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Laurie Lewallen, Advisory 

Committee Coordinator, Office of 

Biotechnology Activities, National Institutes 

of Health, 6705 Rockledge Drive, Room 750, 

Bethesda, MD 20892–7985, 301–496–9838, 

lewallla@od.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

www4.od.nih.gov/oba/, where an agenda and 

any additional information for the meeting 

will be posted when available. 

OMB’s ‘‘Mandatory Information 

Requirements for Federal Assistance Program 

Announcements’’ (45 FR 39592, June 11, 

1980) requires a statement concerning the 

official government programs contained in 

the Catalog of Federal Domestic Assistance. 

Normally NIH lists in its announcements the 

number and title of affected individual 

programs for the guidance of the public. 

Because the guidance in this notice covers 

virtually every NIH and Federal research 

program in which DNA recombinant 

molecule techniques could be used, it has 

been determined not to be cost effective or 

in the public interest to attempt to list these 

programs. Such a list would likely require 

several additional pages. In addition, NIH 

could not be certain that every Federal 

program would be included as many Federal 

agencies, as well as private organizations, 

both national and international, have elected 

to follow the NIH Guidelines. In lieu of the 

individual program listing, NIH invites 

readers to direct questions to the information 

address above about whether individual 

programs listed in the Catalog of Federal 

Domestic Assistance are affected. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.14, Intramural Research 

Training Award; 93.22, Clinical Research 

Loan Repayment Program for Individuals 

from Disadvantaged Backgrounds; 93.232, 

Loan Repayment Program for Research 

Generally; 93.39, Academic Research 

Enhancement Award; 93.936, NIH Acquired 

Immunodeficiency Syndrome Research Loan 

Repayment Program; 93.187, Undergraduate 

Scholarship Program for Individuals from 

Disadvantaged Backgrounds, National 

Institutes of Health, HHS) 

Dated: December 12, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–6081 Filed 12–19–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[FEMA–1732–DR] 

Indiana; Major Disaster and Related 

Determinations 

AGENCY: Federal Emergency 

Management Agency, DHS. 

ACTION: Notice. 

SUMMARY: This is a notice of the 

Presidential declaration of a major 

disaster for the State of Indiana (FEMA–


sroberts on PROD1PC70 with NOTICES